Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 13/20 | 0.41 |
| ▸ | ADH1C | P00326 | 10/20 | 0.41 |
| ▸ | ADH1B | P00325 | 5/20 | 0.41 |
| ▸ | ADH4 | P08319 | 3/20 | 0.41 |
| ▸ | ADH7 | P40394 | 3/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59918 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| Cycloundecane Carbaldehyde SCHEMBL1901240 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL493755 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| Cyclopentanecarbaldehyde SCHEMBL14575123 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL3027683 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL11734533 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL26097 | 1.00 | — | — | |
| SCHEMBL3036861 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL11341547 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| Cyclononanecarbaldehyde SCHEMBL1920808 | 1.00 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115160127-B | Method for preparing long carbon chain dibasic acid through co-oxidation reaction | 中国天辰工程有限公司 | 2024-06-11 | — | — | CN | claimed |
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2612858-A1 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-12-20 | — | — | US | disclosed |
| CN-101909638-B | Optical blurring pigment composition suitable for use in cosmetics | AVON PROD INC | 2012-11-21 | — | — | CN | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8263599-B2 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| WO-2009057811-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
| EP-1957073-A2 | MEDICINAL DRUG | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008044667-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | WO | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-20070010562-A1 | Nr1h4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2007-01-11 | — | — | US | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
| US-4568490-A | REDUCTIVE CONDENSATION WITH A CARBONYL COMPOUND | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1986-02-04 | — | — | US | disclosed |
| US-4537880-A | Aminopropylaminobleomycin derivatives and process for preparation thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | ADH1A 1675/4885ADH1C 1830/4885ADH1B 1522/4885 |
| US-20070010562-A1 | Nr1h4 nuclear receptor binding compounds | NR1H4, NR1H2, NR1H3 | ADH1A 1146/4885ADH1C 2041/4885ADH1B 906/4885 |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | ADH1A 3234/4885ADH1C 3739/4885ADH1B 4121/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | ADH1A 1358/4885ADH1C 1568/4885ADH1B 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.